Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 18/20 | 0.74 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.67 |
| ▸ | CDK1 | P06493 | 2/20 | 0.67 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.67 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | GSK3A | P49840 | 1/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.61 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.61 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26053438 | 0.87 | RIPK1 (0.71) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL31065006 | 0.86 | RIPK1 (1.00) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1780991 | 0.86 | CYP19A1 (0.66) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1780494 | 0.84 | RIPK1 (0.71) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL18741322 | 0.84 | RIPK1 (1.00) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL24655593 | 0.84 | RIPK1 (0.71) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL31065045 | 0.84 | RIPK1 (1.00) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL7892114 | 0.84 | RIPK1 (0.71) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL5907874 | 0.84 | RIPK1 (0.71) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL31265224 | 0.84 | RIPK1 (0.71) | RIPK1CCNB2CDK1CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3870170-B1 | TREATMENT OF PRESBYOPIA AND MYDRIASIS WITH PHENTOLAMINE | OPUS GENETICS INC (US) | 2026-02-25 | — | — | EP | claimed |
| EP-3934624-B1 | TOPICAL COMPOSITION AND METHODS OF MEASURING THE COOLING ABILITY OF A TOPICAL COMPOSITION | FUTURA MEDICAL DEVELOPMENTS LTD (GB) | 2024-03-13 | — | — | EP | claimed |
| EP-1990343-A2 | Azaindoles | Aventis Pharma Limited (GB) | 2008-11-12 | — | — | EP | claimed |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | claimed |
| CN-1665809-A | Azaindoles | AVENTIS PHARMA LTD (GB) | 2005-09-07 | — | — | CN | claimed |
| CN-1615873-A | Azaindoles compound | AVENTIS PHARMA LTD (GB) | 2005-05-18 | — | — | CN | claimed |
| US-20040198737-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-10-07 | — | — | US | claimed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | claimed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | claimed |
| US-20040009983-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-01-15 | — | — | US | claimed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | claimed |
| EP-1263759-A2 | AZAINDOLES | Aventis Pharma Limited (GB) | 2002-12-11 | — | — | EP | claimed |
| WO-2001047922-A2 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2001-07-05 | — | — | WO | claimed |
| EP-4721725-A2 | TREATMENT OF PRESBYOPIA AND MYDRIASIS WITH PHENTOLAMINE | Opus Genetics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4705291-A1 | IKK-ALPHA INHIBITORS | Cancer Research Technology Limited (GB) | 2026-03-11 | — | — | EP | disclosed |
| EP-3870170-B1 | TREATMENT OF PRESBYOPIA AND MYDRIASIS WITH PHENTOLAMINE | OPUS GENETICS INC (US) | 2026-02-25 | — | — | EP | disclosed |
| US-5439917-A | Phenyl-pyrrolo(2,3-b)pyridine antisecretory agent of gastric acid; adenosine triphosphatase enzyme inhibitor | AKTIEBOLAGET ASTRA (SE) | 1995-08-08 | — | — | US | disclosed |
| EP-0580616-A1 | NEW ACTIVE COMPOUNDS | Astra Aktiebolag (SE) | 1994-02-02 | — | — | EP | disclosed |
| EP-0509974-A1 | Pyrrolo[2,3-b]pyridines having therapeutic activity and a process for the preparation thereof | Astra Aktiebolag (SE) | 1992-10-21 | — | — | EP | disclosed |
| WO-1992017477-A1 | NEW ACTIVE COMPOUNDS | AKTIEBOLAGET ASTRA (SE) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198737-A1 | Azaindoles | CCNY, CCNO, CNKSR1 | RIPK1 2247/4885CCNB2 194/4885CDK1 8/4885 |
| US-20040053931-A1 | Azaindoles | CDKN1A, CDK7, CDK2 | RIPK1 1614/4885CCNB2 381/4885CDK1 5/4885 |
| US-20040009983-A1 | Azaindoles | CCNY, CCNO, CKS2 | RIPK1 1843/4885CCNB2 244/4885CDK1 13/4885 |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | MAP3K20, MAP3K12, MAP3K19 | RIPK1 278/4885CCNB2 1015/4885CDK1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.